RBC Capital Markets reissued their outperform rating on shares of Aerie Pharmaceuticals Inc. (NASDAQ:AERI) in a report released on Friday morning. RBC Capital Markets currently has a $55.00 target price on the stock, up from their prior target price of $51.00.

Other analysts also recently issued research reports about the stock. Brean Capital set a $48.00 price objective on shares of Aerie Pharmaceuticals and gave the company a buy rating in a report on Thursday, September 15th. Stifel Nicolaus boosted their price objective on shares of Aerie Pharmaceuticals from $40.00 to $50.00 and gave the company a buy rating in a report on Thursday, September 15th. Needham & Company LLC reissued a buy rating and issued a $52.00 price objective (up previously from $45.00) on shares of Aerie Pharmaceuticals in a report on Thursday, September 15th. Zacks Investment Research raised shares of Aerie Pharmaceuticals from a hold rating to a strong-buy rating and set a $20.00 price objective for the company in a report on Monday, July 4th. Finally, Royal Bank Of Canada boosted their price objective on shares of Aerie Pharmaceuticals from $51.00 to $55.00 and gave the company an outperform rating in a report on Thursday, September 15th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $49.40.

Aerie Pharmaceuticals (NASDAQ:AERI) opened at 38.58 on Friday. The firm has a 50-day moving average of $20.94 and a 200-day moving average of $17.12. The company’s market capitalization is $1.08 billion. Aerie Pharmaceuticals has a 52 week low of $10.82 and a 52 week high of $38.98.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.74) by $0.02. Equities analysts expect that Aerie Pharmaceuticals will post ($2.77) earnings per share for the current fiscal year.

In other news, major shareholder Foresite Capital Fund Ii, L.P. purchased 250,000 shares of the business’s stock in a transaction dated Friday, July 22nd. The stock was bought at an average price of $17.50 per share, with a total value of $4,375,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 8.77% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Barclays PLC increased its stake in shares of Aerie Pharmaceuticals by 3.4% in the second quarter. Barclays PLC now owns 6,015 shares of the company’s stock worth $106,000 after buying an additional 200 shares during the period. ProShare Advisors LLC boosted its position in Aerie Pharmaceuticals by 3.0% in the second quarter. ProShare Advisors LLC now owns 22,695 shares of the company’s stock worth $399,000 after buying an additional 669 shares in the last quarter. Tocqueville Asset Management L.P. boosted its position in Aerie Pharmaceuticals by 1.7% in the second quarter. Tocqueville Asset Management L.P. now owns 42,300 shares of the company’s stock worth $744,000 after buying an additional 725 shares in the last quarter. Geode Capital Management LLC boosted its position in Aerie Pharmaceuticals by 0.6% in the first quarter. Geode Capital Management LLC now owns 161,319 shares of the company’s stock worth $1,961,000 after buying an additional 925 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System boosted its position in Aerie Pharmaceuticals by 4.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 24,578 shares of the company’s stock worth $433,000 after buying an additional 1,019 shares in the last quarter. 99.66% of the stock is owned by institutional investors.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.

5 Day Chart for NASDAQ:AERI

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.